Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financi...(venues projected costs prospects plans a...),Health

Date:3/23/2009

venues, projected costs, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Intermezzo(R) being the first commercially available sleep aid in its target indication; the resources of Transcept being sufficient to enable it to carry out its plans to commercialize Intermezzo(R); the ability of Transcept to secure a primary care marketing partner; and guidance with respect to research and development expenses, general and administrative expenses, and planned marketing partnerships. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including risks related to: the opinion of the FDA on the sufficiency of our NDA to support marketing approval of Intermezzo(R); the commercial attractiveness of Intermezzo(R) to potential primary care marketing partners; commercial acceptance of Intermezzo(R), if approved; unforeseen expenses related to FDA approval, commercialization or our business generally; difficulties or delays in entering into a marketing partnership; our dependence on third parties to manufacture Intermezzo(R); obtaining, maintaining and protecting the intellectual property incorporated into Intermezzo(R); and, if sought, our ability to obtain additional funding to support our business activities. These and other risks are described in greater detail in the "Risk Factors" section of our proxy statement/prospectus/information statement filed with the SEC in connection with our merger with Novacea. Ou
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
2. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
3. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
4. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
5. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
6. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
7. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
8. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
9. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
10. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference